Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dylan Duerre"'
Autor:
David A. Largaespada, James Fisher, Paul D Smith, Alexander W. Coutts, Barbara R. Tschida, Christopher L. Moertel, W. Robert Bell, Adrienne L. Watson, Oona Delpuech, Mark N. Kirstein, Brigitte C. Widemann, Dylan Duerre, Sara H. Osum
Publikováno v:
Neuro-oncology Advances
Background The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim o
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is the most common and malignant primary brain tumor. Novel therapeutic development for GBM is needed since the standard of care universally fails to cure patients and the five-year survival rate remains below 10%. GBM therapeutic
Autor:
Dylan Duerre, David A. Largaespada, Adrienne L. Watson, Mandy Taisto, Sara H. Osum, Christopher L. Moertel, Barbara R. Tschida, Eunice Oribamise, Mark N. Kirstein
Publikováno v:
Neuro Oncol
Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in the neurofibromin 1 (NF1) gene. NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been deve
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is the most common and malignant primary brain tumor. New, effective treatments for GBM are needed since the standard of care universally fails to cure patients. A major hurdle for GBM therapeutic development is the lack of relevan